Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial-Reference-Cited by-同舟云学术

Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial

Published:2018-09-07 Issue:2 Volume:33 Page:295-303
ISSN:0950-222X
Container-title:Eye
language:en
Short-container-title:Eye

Author:

Willcox Abby,Culliford Lucy,Ellis Lucy,Rogers Chris A,Cree Angela^ORCID,Chakravarthy Usha,Ennis Sarah,Behar-Cohen Francine,Reeves Barnaby C^ORCID,Sivaprasad Sobha^ORCID,Lotery Andrew^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

http://www.nature.com/articles/s41433-018-0212-2.pdf

Reference19 articles.

1. Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19–24. PubMed PMID: 11884873.

2. Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond). 2010;24:1743–56. https://doi.org/10.1038/eye.2010.130 . PubMed PMID: 20930852.

3. Schubert C, Pryds A, Zeng S, Xie Y, Freund KB, Spaide RF, et al. Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Hum Mutat. 2014;35:859–67. https://doi.org/10.1002/humu.22551 . PubMed PMID: 24665005; PubMed Central PMCID: PMCPMC4215937.

4. Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S. Photodynamic therapy for central serous chorioretinopathy. Eye (Lond). 2014;28:944–57. Epub 2014/06/21. https://doi.org/10.1038/eye.2014.134. PubMed PMID: 24946843; PubMed Central PMCID: PMCPMC4135258.

5. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115:1756–65. https://doi.org/10.1016/j.ophtha.2008.04.014 . PubMed PMID: 18538401.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eplerenone–A novel Mineralocorticoid receptor antagonist for the clinical application;Environmental Disease;2022

2. The Role of Imaging in Planning Treatment for Central Serous Chorioretinopathy;Pharmaceuticals;2021-01-29

3. Low luminance visual acuity as a clinical measure and clinical trial outcome measure: a scoping review;Ophthalmic and Physiological Optics;2021-01-06

4. Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT;Efficacy and Mechanism Evaluation;2021-01

5. Eplerenone for chronic central serous chorioretinopathy;The Lancet;2020-11